Dr. Peter J. Winkle, MD
Gastroenterology (Gastroenterology Physician)
At a glance
- In the NPI registry since
- 2007
Licensed in California since 1990, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Gastroenterology Physician primary
CA license G70077 (first issued 1990; current) -
Internal Medicine Physician
CA license G70077 (first issued 1990; current)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Industry-funded research
Named as a principal investigator on 30 industry-funded studies in 2025, from 10 companies. The companies reported $22,268,608 in research payments for these studies, mostly to the institutions running them.
- A Phase 1, Randomized, Open-label, Single-dose, Parallel Group Study to Assess the Relative Bioavailability of AMG 133 Administered Using One of Three Drug Products in Participants Living with Overweight or Obesity
Amgen Inc. - An Open-label, Randomized, 2-Part, 4-Period, 2-Sequence, Fully Replicated Crossover Study to Assess the Comparative Bioavailability of BMS-986278 To-be-marketed Formulation Compared to the Phase 3 Clinical Trial Formu…
E.r. Squibb & Sons, L.l.c. - A 2-Part, Phase 1, Randomized, Double-bind, Placebo-controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of Multiple Doses of BMS-986510 Administered as Immediate-Release Capsules or Dual-burst Cap…
E.r. Squibb & Sons, L.l.c. - A Study to Assess the Relative Bioavailability of Risankizumab Following Subcutaneous Administration With On-Body Injector in Healthy Adult Participants
AbbVie Inc. · Completed · NCT06937619 - A Study to Assess the Relative Bioavailability of Two Formulations of Risankizumab Following Subcutaneous Administration With Prefilled Syringes in Healthy Adult Participants
AbbVie Inc. · Completed · NCT06571266 - A Phase 1, Randomized, Double-blind, Multiple-dose Study to Evaluate the Pharmacokinetics of AMG 133 Administered Subcutaneously in Subjects With Overweight or Obesity
Amgen Inc. - Molecule Independent Device Bridging Study
Genentech, Inc. - A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of a Single Dose of Donzakimig in Healthy Chinese and Japanese Participants
UCB SA · Completed · NCT06716879 - A Phase 1 Clinical Study in Healthy Females of Nonchildbearing Potential to Compare the Pharmacokinetics of Sotatercept MK-7962 Administered as a Liquid Formulation in an Autoinjector Versus the Lyophilized Formulation
Merck Sharp & Dohme LLC - A Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Emraclidine in Healthy Adult Western, Japanese, and Han Chinese Subjects
AbbVie Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.